Momentum Builds for ALX Oncology and Delta Apparel
- October 03rd, 2023
- 532 views
Shares of ALX Oncology Holdings Inc. (Nasdaq: ALXO) surged by more than 20% in after-hours trading following the announcement that it will unveil interim Phase 2 ASPEN-06 clinical trial results of evorpacept, aimed at treating advanced HER2-positive gastric cancer, on Tuesday, October 3.
$ALXO was trading at $5.90, marking a substantial increase of $1.09 (+22.66%) during the extended session.
In unrelated news, Delta Apparel, Inc. (NYSE American: DLA) revealed that it has received an unsolicited offer for its Salt Life business unit. The company's Board of Directors has enlisted Baird as its financial advisor for this development. It's important to note that the timing, terms, or structure of any potential transaction, as well as the likelihood of a transaction occurring, remain uncertain.
In after-hours, $DLA was trading at $7.89, up $1.30 (+19.73%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025Earnings Preview: Credo Technology, MongoDB, and Hafnia in Focus
November 30th, 2025
Member Login